Media coverage about Omnicell (NASDAQ:OMCL) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.7314072027516 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
- Zacks: Brokerages Expect Omnicell, Inc. (OMCL) to Announce $0.52 EPS (americanbankingnews.com)
- UPMC Chooses Revolutionary Technology from Omnicell to Elevate and Automate Pharmacy (finance.yahoo.com)
- Omnicell, Inc. – Value Analysis (NASDAQ:OMCL) : December 18, 2017 (finance.yahoo.com)
- Insider Selling: Omnicell, Inc. (OMCL) CFO Sells 1,926 Shares of Stock (americanbankingnews.com)
- Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : December 15, 2017 (finance.yahoo.com)
Shares of Omnicell (NASDAQ:OMCL) opened at $50.50 on Thursday. Omnicell has a 1 year low of $31.85 and a 1 year high of $55.40. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.
Several brokerages have commented on OMCL. Cantor Fitzgerald reiterated a “buy” rating and set a $60.00 target price on shares of Omnicell in a research report on Wednesday, December 13th. Oppenheimer reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Tuesday, December 5th. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Craig Hallum reiterated a “buy” rating and set a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Finally, Benchmark upped their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $55.14.
In other news, VP Peter J. Kuipers sold 3,532 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $50.96, for a total value of $179,990.72. Following the completion of the transaction, the vice president now owns 40,714 shares of the company’s stock, valued at approximately $2,074,785.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Dan S. Johnston sold 14,613 shares of the business’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $47.81, for a total transaction of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares of the company’s stock, valued at approximately $2,085,520.01. The disclosure for this sale can be found here. Insiders sold a total of 31,090 shares of company stock valued at $1,510,221 in the last three months. 3.77% of the stock is owned by company insiders.
WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/12/21/omnicell-omcl-getting-somewhat-favorable-press-coverage-accern-reports.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.